Having a general understanding of what GLP-1 medications do is useful context. But understanding who they are actually designed for — and who may be reaching for a tool that is not the right fit — is a more important and more practical question.
The Medical Standard for Candidacy
GLP-1 medications approved for weight management — specifically Wegovy (semaglutide) and Zepbound (tirzepatide) — have defined clinical criteria. The FDA-approved guidelines establish candidacy as:
- A BMI of 30 or above, or
- A BMI of 27 or above with at least one weight-related comorbidity — such as type 2 diabetes, hypertension, high cholesterol, or obstructive sleep apnea
These thresholds exist because the medications carry real costs — financial, physiological, and practical — and the risk-benefit calculation shifts considerably depending on the individual's starting point. For type 2 diabetes specifically, lower-dose GLP-1 medications are prescribed even without weight loss as the primary objective, due to their documented cardiovascular protective effects and blood sugar management benefits.
"These are prescription medications with real pharmacological effects — not supplements with a low bar for use. The clinical candidacy threshold exists precisely because the risk-benefit calculation is not the same for everyone."
The Ideal Profile for GLP-1 Use
Beyond meeting basic BMI criteria, certain profiles represent stronger candidates for meaningful benefit from GLP-1 medications.
People with a significant amount of weight to lose — generally 30 or more pounds — related to metabolic dysfunction or appetite dysregulation tend to experience the most pronounced response. This is meaningfully different from someone who is 10–15 pounds above their desired weight and primarily seeking an aesthetic outcome. That population is not who these medications were developed for, and using them in that context often produces a different risk-benefit picture.
People with documented insulin resistance, prediabetes, or type 2 diabetes are well-supported by the clinical literature. The dual benefit — improved blood sugar regulation alongside meaningful weight reduction — creates a strong case. People who have made genuine and sustained attempts at lifestyle modification without achieving adequate results are the original target population. These medications were not designed as a shortcut; they were designed for cases where conventional approaches have proven genuinely insufficient.
Who Should Approach With Caution
There are contraindications and cautions worth knowing before pursuing GLP-1 medications.
People with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) are advised against GLP-1 receptor agonists. These conditions are relatively rare, but the precaution is standard across prescribing guidelines.
People with a history of pancreatitis should discuss this carefully with their prescribing physician, as GLP-1 medications have been associated with pancreatitis risk in some studies, though causality in the broader population remains debated.
People who are pregnant or planning to become pregnant should not use these medications.
The Lifestyle Prerequisite Nobody Discusses
The clinical trials that produced the headline weight loss numbers were conducted with participants who were also receiving behavioral intervention — dietary counseling, physical activity guidance, and ongoing lifestyle support. The medication was not studied or intended to function in isolation.
In practice, the best outcomes consistently come from people who pair GLP-1 use with intentional nutrition and adequate physical activity. The medication creates more favorable conditions for progress. What you do within those conditions determines whether the result is lasting or temporary. This isn't a warning label — it is the mechanism by which these medications produce durable outcomes rather than short-term losses that reverse once the prescription ends.
Questions Worth Discussing With Your Provider
- Am I actually a clinical candidate based on current guidelines?
- Do I have any contraindications that should be evaluated before starting?
- What is a realistic expectation for my specific situation and starting point?
- What nutritional and lifestyle support should accompany this medication?
- What is the plan for long-term use or eventual discontinuation?
- How will we monitor and evaluate my response over time?
The Bottom Line
GLP-1 medications are well-matched tools for specific populations — those with significant metabolic burden, clinically elevated BMI, and a genuine need for pharmacological support alongside lifestyle work. They are not designed for cosmetic fat loss in otherwise healthy individuals, and they do not produce lasting results in the absence of nutritional structure. The next article in this series addresses what happens — and why — when people misunderstand that second point.